Nephrogenic diabetes insipidus secondary to COVID-19 infection in a patient on lithium medication: a case report
- Author:
Jong-In CHOI
1
;
Somin LEE
;
Hyun Lee KIM
;
Jong-Hoon CHUNG
;
Byung Chul SHIN
;
Youngmin YOON
Author Information
1. Department of Internal Medicine, Haenam Woori General Hospital, Haenam, Korea
- Publication Type:Case Report
- From:Journal of the Korean Society of Emergency Medicine
2025;36(1):41-44
- CountryRepublic of Korea
- Language:English
-
Abstract:
Nephrogenic diabetes insipidus (NDI) is characterized by polyuria and polydipsia, high serum osmolality, and low urine osmolality because of resistance to antidiuretic hormone. Lithium is commonly used to treat psychiatric disorders, and NDI is one of the common renal side effects of lithium therapy. On the other hand, NDI induced by lithium medication in a patient after a coronavirus disease-19 (COVID-19) infection has not been reported. This paper presents a patient who developed new-onset NDI secondary to a COVID-19 infection despite being on a stable lithium dose for several years. This case highlights the importance of considering a COVID-19 infection as a possible cause of NDI in patients taking lithium medication.
